SUMMARY In this study we used restriction endonuclease mapping to characterise the molecular defect responsible for haemoglobin H disease in 14 Sardinian children. The resulting genotypes were then correlated with the respective clinical and haematological phenotypes. We found that patients with the combination of non-deletion xc+-thalassaemia [(oc)th] and deletion cx°-thalassaemia (--Med) have a more severe phenotype than that resulting from the interaction of deletion Occthalassaemia (__Med) and a+-thalassaemia (-oc) determinants. Clinically, presentation was earlier and with moderate anaemia or haemolytic crisis, enlargement of the liver and spleen, and thalassaemic bone changes. Haematologically, the anaemia was more severe and there were higher bilirubin levels, reticulocyte counts, Hb H levels, and percentage of red blood cells with inclusion bodies. These results suggest that in those Hb H disease patients with the non-deletion [(ccc)th] determinant, two a globin genes produce fewer oc globin chains than a single cx globin locus.
The two x globin structural genes lie on chromosome 16 linked to one g globin gene, a ¢-like gene (N.i), and an a-like pseudogene (y cx,) in the order 5'-(2-p 3'i 2 Several different lesions of this gene complex produce the cx-thalassaemias, a group of genetic disorders characterised by a reduced or absent output of oc globin chains within the red blood cells.
Haemoglobin H (Hb H) disease, the most important clinical form of oc-thalassaemia, is a hereditary microcytic anaemia most frequently found in South Asian and Mediterranean populations.3 Most commonly, this disorder results from the interaction of a deletion form of ac°-thalassaemia (--) with a deletion c+-thalassaemia (-a) determinant.4-6 However, this condition can also be produced either by the combination of a deletion form of cc°-thalassaemia (--) with a non-deletion oc+-thalassaemia determinant [(CXCX)th]6-9 or by the homozygous state of a non-deletion defect [(aCC) th/(ac )th], so far seen only in Saudi Arabs.'0
The cx°-thalassaemia determinant, characterised by a complete suppression of cc globin chain production, includes haplotypes with loss of both cx globin structural loci as well as haplotypes with residual but non-functional cx globin genes.6 11-13 *On leave fronm the Howard Hughes Medical Institute Laboratory and the Department of Medicine, University of California, San Francisco, USA.
Received for publication 7 January 1983. Accepted for publication 25 with the non-deletion lesion the hepatosplenomegaly was quite pronounced with the lower tip 5 cm below the costal margin. The course of the disease was more severe in those patients with the non-deletion genotype, who showed more persistent jaundice and who frequently experienced a critical episodic aggravation of the anaemia or a frank haemolytic crisis, occasionally severe enough to require blood transfusion (Hb < 5 g/dl), following infections or oxidant drug administration, but sometimes even without any specific associated event. On the other hand, patients with the deletion genotype had a milder course which was characterised by a minimal fluctuation in the intensity of the anaemia. A haemolytic crisis was observed only once in one patient in this group, who was also a carrier of the G6PD defect of the Mediterranean type.
None of the patients in either group had leg ulcers or gall stones.
HAEMATOLOGICAL FINDINGS
Because of fluctuating Hb levels or the development of frank haemolytic crisis, there was a marked variation in the haematological findings within the 1 to 6 years longitudinal study in both groups. Therefore, we compared the means of repeated determinations carried out at follow-up instead of the single values at presentation.
Patients with the non-deletion lesion showed more severe anaemia, significantly higher bilirubin levels, reticulocyte count, Hb H levels, and percentage of red blood cells with inclusion bodies, and significantly lower Hb A2 levels compared with those with the more usual deletion lesions.
Regardless of the genotype, both groups of patients showed cx/5 globin chain synthesis ratios within the range already reported in Hb H disease subjects.
There were no differences in platelet and white blood cell counts.
Discussion
In this study we defined by restriction endonuclease mapping the molecular defect in 14 Sardinians with the clinical and haematological phenotype of Hb H disease. In nine of the 14 patients, the underlying molecular defect was found to be the deletion of three of the four a globin structural genes (--/-cL).
In the remaining five we found a combination of the deletion of two oc globin genes in one chromosome (--) with a non-deletion lesion [(oa)th], as yet incompletely characterised, in the other. We then compared the clinical and haematological phenotypes of these two groups of patients with Hb H disease resulting from these different molecular mechanisms. Our results clearly show that the Hb H disease phenotype produced by the combination between the deletion (--) and non-deletion [(ococ)th] determinants is more severe than that resulting from the more common deletion genotype (--/-oc). Those patients with the non-deletion lesion, in fact, presented earlier with a moderate anaemia or with a frank haemolytic crisis. At follow-up, in those patients with the non-deletion lesion, thalassaemialike bone changes and enlargment of the liver and spleen were observed more frequently and were more marked. Furthermore, the course of the disease was more severe in patients with the non-deletion lesion because of episodic worsening of the anaemia or development of frank haemolytic crises. Accordingly, mean Hb levels from repeated determinations carried out over the period of follow-up were lower and bilirubin levels higher in those patients with the non-deletion defect.
Such clinical effects could well result from an increased red blood cell destruction rate in the spleen, or more intense ineffective erythropoiesis in the bone marrow of patients with the non-deletion as compared to those with the deletion lesion, or both. Although the large gap in our knowledge about the pathophysiology of Hb H disease precludes giving a precise outline of the mechanisms underlying these clinical differences, from our 
